APLIF Stock Chart & Stats
$0.01
>-$0.01(-1.27%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-1.27%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume80.20K
Average Volume (3M)8.77K
Market Cap
$927.65K
Enterprise Value$15.17M
Total Cash (Recent Filing)$138.68K
Total Debt (Recent Filing)$13.33M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding132,366,120
10 Day Avg. Volume1,094
30 Day Avg. Volume8,771
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market Cap16.36
Enterprise Value/Revenue40.05
Enterprise Value/Gross Profit40.68
Enterprise Value/Ebitda-2.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reported Revenue GrowthThe reported revenue growth rate indicates that the company has expanded its current revenue base materially. If supported by continued development progress and customer or partner activity, this growth can improve operating leverage and strengthen the commercial foundation over the next several quarters.
High Gross MarginA gross margin near 97% suggests that successful products or commercial arrangements could retain substantial value after direct costs. This provides a potentially attractive economic structure for future scale, although operating profitability still depends on controlling development and corporate expenses.
Focused Infectious-Disease StrategyA focused strategy in infectious diseases gives Appili a defined area for advancing drug candidates through clinical and regulatory pathways. Concentrating on unmet medical needs can support differentiated development priorities and create opportunities for future partnering or commercialization.
Bears Say
Severely Stressed Balance SheetNegative equity and debt that materially exceeds the asset base indicate very limited financial flexibility. This structure can constrain investment in clinical programs, increase refinancing dependence, and raise the likelihood that future funding could dilute existing shareholders.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its activities. Continued cash consumption increases dependence on external financing and may force management to prioritize programs or seek capital before development milestones are reached.
Deep Losses And Limited ScaleVery small revenue alongside substantial operating and net losses shows that the company has not yet achieved meaningful commercial scale or sustained breakeven. This weak earnings base limits internally generated funding and leaves results highly dependent on development success.
Appili Therapeutics Inc Class A News
APLIF FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is $927.65K.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Nov 12, 2026 which is in 30 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Aug 14, 2026. The company reported -$0.009 earnings per share for the quarter.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -$0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in APLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).